ImmunityBio: FDA Approval Gets Ball Rolling Towards Next Set Of Indications [Seeking Alpha]
ImmunityBio, Inc. (IBRX)
Company Research
Source: Seeking Alpha
The global bladder cancer market could reach $11.5 billion by 2032. Company also tends to evaluate the use of ANKTIVA towards other cancer indications such as acute myeloid leukemia and platinum-resistant ovarian cancer. A $100 million payment based on a royalty agreement was contingent upon receiving FDA approval of ANKTIVA for the treatment of patients with BCG-unresponsive NMIBC. ImmunityBio, Inc. NASDAQ: IBRX ) was able to plus Bacillus Calmette-Guerin [BCG] for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer [NMIBC] with carcinoma in situ [CIS], with or without Recommended For You Recommended For You About IBRX Stock
Show less
Read more
Impact Snapshot
Event Time:
IBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBRX alerts
High impacting ImmunityBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBRX
News
- ImmunityBio partners with Serum Institute for BCG vaccines [Yahoo! Finance]Yahoo! Finance
- ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types [Yahoo! Finance]Yahoo! Finance
- ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer TypesBusiness Wire
- ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association [Yahoo! Finance]Yahoo! Finance
- ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological AssociationBusiness Wire
IBRX
Earnings
- 8/8/23 - Miss
IBRX
Sec Filings
- 5/3/24 - Form EFFECT
- 4/29/24 - Form DEFA14A
- 4/29/24 - Form DEF
- IBRX's page on the SEC website